PMID- 10568829
OWN - NLM
STAT- MEDLINE
DCOM- 19991227
LR  - 20190516
IS  - 1019-6439 (Print)
IS  - 1019-6439 (Linking)
VI  - 15
IP  - 6
DP  - 1999 Dec
TI  - Expression of fibroblast growth factor and FGF-receptor family genes in human
      myeloma cells, including lines possessing t(4;14)(q16.3;q32. 3) and FGFR3
      translocation.
PG  - 1205-12
AB  - Recently several chromosomal translocations involved in myeloma cases and myeloma
      cell lines; i.e., t(11;14)(q13;q32), t('8;14)(q24;q32), t(4;14)(q16.3;q32.3),
      t(6;14)(p25;q32), and t(14;16)(q32.3;q23), have been identified. These
      translocations are considered to dysregulate genes which may be concerned with
      myelomagenesis; i.e., PRAD1/cyclin D1, the c-myc oncogene, FGFR3 (fibroblast
      growth factor receptor 3), MMSET (multiple myeloma SET domain), MUM1 (multiple
      myeloma oncogene 1)/IRF4 (interferon regulatory factor 4), and the c-maf
      oncogene, respectively. However, the cellular biological roles of these genes
      have not yet been elucidated in myeloma cells. Because two of the seven human
      myeloma cell lines which were established at Kawasaki Medical School, Okayama,
      Japan, KMS-11 and KMS-18, have been proven to possess t(4;14)(q16.3;q32.3), we
      studied the expression levels of the FGFR3 gene in these seven cell lines and 13 
      primary myeloma specimens. The expression levels of 12 known FGF family genes
      (FGF-1 to 12) and 4 FGFR genes (FGFR1 to 4) were also examined in seven cell
      lines. In addition, the growth status of the KMS-11 and KMS-18 lines with FGF-1
      or anti-FGF-4 neutralizing monoclonal antibody (MoAb) supplementation was
      investigated because FGF-1 and 4 are known as the principal ligands for FGFR3.
      FGFR3 overexpression was observed in both of the cell lines possessing
      t(4;14)(q16.3;q32.3) and in 3 of 13 case specimens. Anti-FGF-4 neutralizing MoAb 
      caused significant growth inhibition in these two cell lines possessing
      t(4;14)(q16.3;q32.3). These findings indicate that t(4;14) (q16. 3;q32.3) may
      provide myeloma cells with a growth advantage via an autocrine mechanism between 
      FGFR3 and FGF-4.
FAU - Otsuki, T
AU  - Otsuki T
AD  - Department of Hygiene, Kawasaki Medical School, Kurashiki, Okayama 701-0192,
      Japan.
FAU - Yamada, O
AU  - Yamada O
FAU - Yata, K
AU  - Yata K
FAU - Sakaguchi, H
AU  - Sakaguchi H
FAU - Kurebayashi, J
AU  - Kurebayashi J
FAU - Nakazawa, N
AU  - Nakazawa N
FAU - Taniwaki, M
AU  - Taniwaki M
FAU - Yawata, Y
AU  - Yawata Y
FAU - Ueki, A
AU  - Ueki A
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Greece
TA  - Int J Oncol
JT  - International journal of oncology
JID - 9306042
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (DNA, Complementary)
RN  - 0 (FGF4 protein, human)
RN  - 0 (Fibroblast Growth Factor 4)
RN  - 0 (Protein Isoforms)
RN  - 0 (Proto-Oncogene Proteins)
RN  - 0 (RNA, Neoplasm)
RN  - 0 (Receptors, Fibroblast Growth Factor)
RN  - 103107-01-3 (Fibroblast Growth Factor 2)
RN  - 104781-85-3 (Fibroblast Growth Factor 1)
RN  - 62031-54-3 (Fibroblast Growth Factors)
RN  - EC 2.7.10.1 (FGFR3 protein, human)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
RN  - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 3)
SB  - IM
MH  - Aged
MH  - Antibodies, Monoclonal/pharmacology
MH  - Cell Division/drug effects
MH  - Cell Line, Transformed
MH  - Chromosomes, Human, Pair 14/*genetics
MH  - Chromosomes, Human, Pair 4/*genetics
MH  - DNA, Complementary/genetics
MH  - Female
MH  - Fibroblast Growth Factor 1
MH  - Fibroblast Growth Factor 2/genetics/immunology
MH  - Fibroblast Growth Factor 4
MH  - Fibroblast Growth Factors/*genetics/immunology
MH  - Gene Expression Regulation, Neoplastic
MH  - HL-60 Cells
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multiple Myeloma/*genetics/pathology
MH  - Protein Isoforms/genetics
MH  - *Protein-Tyrosine Kinases
MH  - Proto-Oncogene Proteins/genetics/immunology
MH  - RNA, Neoplasm/genetics/isolation & purification
MH  - Receptor, Fibroblast Growth Factor, Type 3
MH  - Receptors, Fibroblast Growth Factor/*genetics
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Translocation, Genetic
MH  - Tumor Cells, Cultured
EDAT- 1999/11/24 00:00
MHDA- 1999/11/24 00:01
CRDT- 1999/11/24 00:00
PHST- 1999/11/24 00:00 [pubmed]
PHST- 1999/11/24 00:01 [medline]
PHST- 1999/11/24 00:00 [entrez]
AID - 10.3892/ijo.15.6.1205 [doi]
PST - ppublish
SO  - Int J Oncol. 1999 Dec;15(6):1205-12. doi: 10.3892/ijo.15.6.1205.